These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7704494)

  • 1. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer.
    Klastersky J; Sculier JP; Ries F; Dabouis G; Libert P; Schmerber J; Thiriaux J; Berchier MC; Bureau G; Van Cutsem O
    Lung Cancer; 1994 Dec; 11(5-6):373-84. PubMed ID: 7704494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working Party.
    Klastersky J; Sculier JP; Ries F; Dabouis G; Libert P; Schmerber J; Thiriaux J; Berchier MC; Bureau G; Van Cutsem O
    Ann Oncol; 1994 Sep; 5(7):641-3. PubMed ID: 7993841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer].
    Fujii M; Kiura K; Okabe K; Toki H; Kimura M
    Gan To Kagaku Ryoho; 1987 Sep; 14(9):2676-81. PubMed ID: 2820312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Français de Pneumo-Cancérologie'.
    Pérol M; Guérin JC; Thomas P; Poirier R; Carles P; Robinet G; Kleisbauer JP; Paillotin D; Vergnenègre A; Balmes P; Touron D; Grivaux M; Pham E
    Lung Cancer; 1996 Feb; 14(1):119-34. PubMed ID: 8696715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.
    Crino L; Tonato M; Darwish S; Meacci ML; Corgna E; Di Costanzo F; Buzzi F; Fornari G; Santi E; Ballatori E
    Cancer Chemother Pharmacol; 1990; 26(1):52-6. PubMed ID: 2157554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
    Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
    Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer.
    Stockler M; Raghavan D; McCaughan BC; Grygiel J; McNeil E; Gianoutsos P; Lee JH
    Med J Aust; 1992 May; 156(10):698-700. PubMed ID: 1377770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
    Gridelli C; Perrone F; Palmeri S; D'Aprile M; Cognetti F; Rossi A; Gebbia V; Pepe R; Veltri E; Airoma G; Russo A; Incoronato P; Scinto AF; Palazzolo G; Natali M; Leonardi V; Gallo C; De Placido S; Bianco AR
    Ann Oncol; 1996 Oct; 7(8):821-6. PubMed ID: 8922196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer.
    Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Saijo N
    Eur J Cancer; 1991; 27(5):571-5. PubMed ID: 1647183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center.
    Joss RA; Bürki K; Dalquen P; Schatzmann E; Leyvraz S; Cavalli F; Ludwig C; Siegenthaler P; Alberto P; Stahel R
    Cancer; 1990 Jun; 65(11):2426-34. PubMed ID: 2159837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of combination chemotherapy with mitomycin C, vindesine and cisplatin (MVP therapy) in advanced non-small cell lung cancer].
    Setoguchi J; Sawada M; Onodera H; Sigeta M; Nakai M; Nakano K; Kanatsuna T; Kondoh M; Hotta T; Hayashi H
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2399-403. PubMed ID: 2546504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques).
    Riggi M; Ruffie P; Voisin S; Monnet I; de Cremoux H; Saltiel JC; Martin M; Vergne L; Huet J; Cvitkovic E
    Eur J Cancer; 1991; 27(10):1238-42. PubMed ID: 1659842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer].
    Hayashi Y; Kato M; Matsuura T; Yamada Y; Adachi S; Ito G; Yamamoto K; Takeuchi T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1455-60. PubMed ID: 2167632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer.
    Einhorn LH; Loehrer PJ; Williams SD; Meyers S; Gabrys T; Nattan SR; Woodburn R; Drasga R; Songer J; Fisher W
    J Clin Oncol; 1986 Jul; 4(7):1037-43. PubMed ID: 3088219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results.
    Tejedor M; Valerdi JJ; López R; Domínguez MA; Arias F; Illarramendi JJ; Martínez E
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):813-8. PubMed ID: 7860393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.
    Burkes RL; Ginsberg RJ; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Cooper JD
    J Clin Oncol; 1992 Apr; 10(4):580-6. PubMed ID: 1312587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
    Fukuoka M; Masuda N; Furuse K; Negoro S; Takada M; Matsui K; Takifuji N; Kudoh S; Kawahara M; Ogawara M
    J Clin Oncol; 1991 Apr; 9(4):606-13. PubMed ID: 1648597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
    Takifuji N; Fukuoka M; Negoro S; Takada M; Kusunoki Y; Matsui K; Masuda N; Ryu S; Sakai N; Kubota K
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):429-34. PubMed ID: 2157364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer. A phase II study.
    Fukuoka M; Negoro S; Masuda N; Kusunoki Y; Matsui K; Ryu S; Takifuji N; Kudoh S; Takada M
    Am J Clin Oncol; 1992 Feb; 15(1):18-22. PubMed ID: 1312768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.